MiMedx Group (MDXG) to Release Quarterly Earnings on Tuesday

MiMedx Group (NASDAQ:MDXG - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties interested in registering for the company's conference call can do so using this link.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by ($0.04). MiMedx Group had a return on equity of 41.12% and a net margin of 14.49%. The company had revenue of $86.83 million for the quarter, compared to analyst estimates of $85.58 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG traded up $0.15 on Tuesday, reaching $6.51. 747,281 shares of the company were exchanged, compared to its average volume of 761,862. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. MiMedx Group has a 1-year low of $3.49 and a 1-year high of $9.27. The firm has a market cap of $956.71 million, a price-to-earnings ratio of 20.34 and a beta of 1.32. The company has a 50-day moving average of $7.57 and a 200-day moving average of $7.58.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Mizuho boosted their price objective on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Lake Street Capital assumed coverage on shares of MiMedx Group in a research report on Thursday, March 7th. They issued a "buy" rating and a $12.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.25.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, COO Ricci S. Whitlow sold 15,493 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $8.07, for a total value of $125,028.51. Following the transaction, the chief operating officer now directly owns 416,321 shares in the company, valued at approximately $3,359,710.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, COO Ricci S. Whitlow sold 15,493 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $8.07, for a total transaction of $125,028.51. Following the transaction, the chief operating officer now directly owns 416,321 shares in the company, valued at approximately $3,359,710.47. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO William Frank Iv Hulse sold 20,381 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total transaction of $162,028.95. Following the transaction, the chief accounting officer now owns 479,959 shares in the company, valued at $3,815,674.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,145 shares of company stock worth $409,378. Corporate insiders own 19.90% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.